Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mBTC vax + poly-ICLC
- Development stage
- Unknown
- Lead developer
- Johns Hopkins University
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
mBTC vax + poly-ICLC is a combination immunotherapy consisting of a personalized mutant peptide-based cancer vaccine (mBTC vax) administered together with the immune adjuvant poly-ICLC. The mBTC vax component is a peptide vaccine designed to target tumor-specific neoantigens derived from patient-specific mutations. Poly-ICLC (Hiltonol) is a synthetic double-stranded RNA that acts as an agonist for Toll-like receptor 3 (TLR3) and melanoma differentiation-associated gene 5 (MDA5), mimicking viral infection to stimulate innate immunity. As an adjuvant, poly-ICLC enhances dendritic cell maturation and promotes robust CD4+ and CD8+ T cell responses against tumor antigens presented by the vaccine[3][4][6]. This combination has been investigated in early-phase clinical trials for various cancers including glioblastoma, pancreatic cancer, and melanoma[3][5][7]. The primary mechanism involves induction of antigen-specific cytotoxic T lymphocytes through enhanced antigen presentation and pro-inflammatory cytokine production.
- Other names
- mBTCvaxPolyinosinic-polycytidylic acid stabilized with poly-L-lysine and carboxymethylcellulosePoly(IC:LC)
02
Targets
IFIH1 (MDA5)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on mBTC vax + poly-ICLC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mBTC vax + poly-ICLC.